TY  - JOUR
AU  - Peters, Solange
AU  - Danson, Sarah
AU  - Hasan, Baktiar
AU  - Dafni, Urania
AU  - Reinmuth, Niels
AU  - Majem, Margarita
AU  - Tournoy, Kurt G
AU  - Mark, Michael T
AU  - Pless, Miklos
AU  - Cobo, Manuel
AU  - Rodriguez-Abreu, Delvys
AU  - Falchero, Lionel
AU  - Moran, Teresa
AU  - Ortega Granados, Ana Laura
AU  - Monnet, Isabelle
AU  - Mohorcic, Katja
AU  - Sureda, Bartomeu Massutí
AU  - Betticher, Daniel
AU  - Demedts, Ingel
AU  - Macias, Jose Antionio
AU  - Cuffe, Sinead
AU  - Luciani, Andrea
AU  - Sanchez, Jose Garcia
AU  - Curioni-Fontecedro, Alessandra
AU  - Gautschi, Oliver
AU  - Price, Gillian
AU  - Coate, Linda
AU  - von Moos, Roger
AU  - Zielinski, Christoph
AU  - Provencio, Mariano
AU  - Menis, Jessica
AU  - Ruepp, Barbara
AU  - Pochesci, Alessia
AU  - Roschitzki-Voser, Heidi
AU  - Besse, Benjamin
AU  - Rabaglio, Manuela
AU  - O'Brien, Mary E R
AU  - Stahel, Rolf A
PY  - 2020
DO  - 10.1016/j.jtho.2020.06.011
UR  - http://hdl.handle.net/10668/15788
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - Receptor activator of NF-kB ligand stimulates NF-kB-dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid tumors...
LA  - en
KW  - Bone metastases
KW  - Denosumab
KW  - NSCLC
KW  - RANK
KW  - RANKL
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Denosumab
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Reference Standards
KW  - Retrospective Studies
TI  - A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
TY  - research article
VL  - 15
ER  -